Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 3—March 2025
Research Letter
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Valentina Gerussi
, Tania Petersen, Isabelle Bonnet, Alexandra Aubry, Marwa Bachir, Esther Gyde, Florence Morel, Corentin Poignon, Brigitte Rached, Valérie Pourcher, Christophe Rioux, Dorothée Vallois, Nicolas Veziris, Jérôme Robert, and Lorenzo Guglielmetti
, Tania Petersen, Isabelle Bonnet, Alexandra Aubry, Marwa Bachir, Esther Gyde, Florence Morel, Corentin Poignon, Brigitte Rached, Valérie Pourcher, Christophe Rioux, Dorothée Vallois, Nicolas Veziris, Jérôme Robert, and Lorenzo Guglielmetti
Table
Phenotypic and genotypic methods for MDR TB isolates identified in France during 2008–2022 used in evaluation of high-dose isoniazid use in MDR TB treatment*
| Isoniazid resistance | All isolates, n = 958 | Isolates from patients eligible for SCR, n = 739 |
|---|---|---|
| Phenotypic isoniazid resistance | ||
| High-level resistance† | 892 (93.1; 91.5–94.7) | 677 (91.6; 89.6–93.6) |
| Low-level resistance‡ |
66 (6.9; 5.3–8.5) |
62 (8.4; 6.4–10.4) |
| Genotypic isoniazid resistance | ||
| katG + inhA or its promoter mutation | 161 (16.8; 14.4–19.2) | 104 (14.1; 11.6–16.6) |
| katG mutation alone | 676 (70.6; 67.7–73.5) | 525 (71.0; 67.8–74.3) |
| inhA or its promoter mutation alone | 98 (10.2; 8.3–12.1) | 89 (12.1; 9.7–14.4) |
| No mutation |
23 (2.4; 1.4–3.4) |
21 (2.8; 1.6–4.0) |
| Diagnostic accuracy of genotypic testing (katG mutation) to predict high-level isoniazid resistance, % (95% CI) | ||
| Sensitivity | 93.3 (91.6–94.9) | 92.3 (90.4–94.3) |
| Specificity | 86.4 (84.2–88.6) | 87.3 (84.8–89.7) |
| Positive predictive value | 99.0 (98.4–99.7) | 98.9 (98.1–99.7) |
| Negative predictive value | 46.4 (43.2–49.6) | 48.5 (44.8–52.1) |
*Values are no. (%; 95% CI) except as indicated. MDR TB, multidrug-resistant TB; SCR, short course regimen. †Defined as resistance to the 1.0 µg/mL dose. ‡Defined as resistance to the 0.2 µg/mL dose.
Page created: January 07, 2025
Page updated: February 21, 2025
Page reviewed: February 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.